Evaluation of the predictive role of tumor immune infiltrate in HER2-positive breast cancer patients treated with neoadjuvant anti-HER2 therapy without chemotherapy

BACKGROUND: Tumor infiltrating lymphocytes (TILs) are associated with benefit to trastuzumab and chemotherapy in early-stage HER2+ breast cancer (BC) patients. The predictive value of TILs, TIL subsets, and other immune cells in patients receiving chemotherapy-sparing lapatinib plus trastuzumab (LT)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: De Angelis, Carmine, Nagi, Chandandeep, Hoyt, Cliff C., Liu, Linying, Roman, Kristin, Wang, Chichung, Zheng, Yi, Veeraraghavan, Jamunarani, Sethunath, Vidyalakshmi, Nuciforo, Paolo, Wang, Tao, Tsimelzon, Anna, Mao, Sufeng, Hilsenbeck, Susan G., Trivedi, Meghana V., Cataldo, Maria Letizia, Pavlick, Anne C., Wolff, Antonio C., Weigelt, Britta, Reis-Filho, Jorge S., Prat, Aleix, Gutierrez, Carolina, Osborne, C. Kent, Rimawi, Mothaffar F., Schiff, Rachel
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7002194/
https://ncbi.nlm.nih.gov/pubmed/31653641
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-1402
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados